Michelle Jansman
@michellejansman.bsky.social
Researcher at DTU Health Tech and Stanford School of Medicine | Nanoparticle formulation | Oxygen carriers | Tissue engineering
It shows that each approach has its adv/disadvantages, whether using stem cells or particle systems.
While I am more interested in the latter, it is good to follow all the progresses made in each approach. Knowing a clinical trial was done in 2022 shows great promise for artificial blood!
While I am more interested in the latter, it is good to follow all the progresses made in each approach. Knowing a clinical trial was done in 2022 shows great promise for artificial blood!
March 10, 2025 at 6:17 PM
It shows that each approach has its adv/disadvantages, whether using stem cells or particle systems.
While I am more interested in the latter, it is good to follow all the progresses made in each approach. Knowing a clinical trial was done in 2022 shows great promise for artificial blood!
While I am more interested in the latter, it is good to follow all the progresses made in each approach. Knowing a clinical trial was done in 2022 shows great promise for artificial blood!